Updates are available Correction dated 2023-09-04
Click to view Correction: https://doi.org/10.1186/s13075-023-03160-1
-
Authors
Akthar, Mumina
Nair, Nisha
Carter, Lucy M.
Vital, Edward M.
Sutton, Emily
McHugh, Neil
,
Gordon, Patrick
Young-Min, Steven
Stevens, Robert
Prabu, Athiveer
Batley, Mike
Gendi, Nagui
Dasgupta, Bhaskar
Khamashta, Munther
Hewins, Peter
Stratton, Richard J.
Chan, Antoni
De Lord, Denise
King, Jon
Dubey, Shirish
O’Riordan, Edmond
Shaffu, Shireen
Laversuch, Cathy
Sheeran, Thomas P.
Vermaak, Erin
Erb, Nicola
Pyne, Debasish
Jeffrey, Rachel
Youssef, Hazem
Al-Allaf, Wahab
Regan, Marian
Kaul, Arvind
,
Payne, Katherine
Lunt, Mark
Peek, Niels
Geifman, Nophar
Gavan, Sean
Armitt, Gillian
Doherty, Patrick
Prattley, Jennifer
Azadbakht, Narges
Papazian, Angela
Le Sueur, Helen
Farrelly, Carmen
Richardson, Clare
Shabbir, Zunnaira
Hewitt, Lauren
Gordon, Caroline
Young, Stephen
Jayne, David
Farewell, Vern
Su, Li
Pickering, Matthew
Lightstone, Elizabeth
Gilmore, Alyssa
Botto, Marina
Vyse, Timothy
Morris, David Lester
D’Cruz, David
Wittmann, Miriam
Emery, Paul
Beresford, Michael
Hedrich, Christian
Midgley, Angela
Gritzfeld, Jenna
Ehrenstein, Michael
Isenberg, David
Parvaz, Mariea
Dunnage, Jane
Batchelor, Jane
Holland, Elaine
Upsall, Pauline
Bruce, Ian N.
Reynolds, John A.
- License Information
-
More Information
Article History
Received: 25 January 2023
Accepted: 9 June 2023
First Online: 30 June 2023
Change Date: 4 September 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13075-023-03160-1
Declarations
:
: Ethical approval was granted by North West Greater Manchester West Research Ethics Committee (09/H1014/64) and the local Research and Development departments at participant sites.
: Not applicable.
: INB has received grant/research support from Genzyme/Sanofi, GlaxoSmithKline, Roche, and UCB; received consulting fees from Eli Lilly, GlaxoSmithKline, ILTOO, Merck Serono, and UCB; and was a speaker for AstraZeneca, GlaxoSmithKline, and UCB. EMV has received consultancy fees from Roche, GSK, AstraZeneca, Aurinia Pharmaceuticals, Lilly and Novartis. All other authors have declared no competing interests.
